doi: 10.1007/s00108-024-01822-z.
Epub 2024 Dec 30.
[Iscalimab-New treatment option for patients with primary Sjögren's disease]
[Article in
German]
Affiliations
- PMID: 39738525
- DOI: 10.1007/s00108-024-01822-z
Item in Clipboard
[Iscalimab-New treatment option for patients with primary Sjögren's disease]
[Article in
German]
Inn Med (Heidelb).
2025 Feb.
No abstract available
Conflict of interest statement
Einhaltung ethischer Richtlinien. Interessenkonflikt: T. Dörner: Finanzierung von klinischen Studien (an die Charité) durch Novartis, die jedoch nicht Iscalimab betrifft. A. Aue und S. Nitschmann geben an, dass kein Interessenkonflikt besteht. Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Similar articles
-
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.Lancet. 2024 Aug 10;404(10452):540-553. doi: 10.1016/S0140-6736(24)01211-X. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096929 Clinical Trial.
-
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.Curr Opin Rheumatol. 2020 Nov;32(6):609-616. doi: 10.1097/BOR.0000000000000754. Curr Opin Rheumatol. 2020. PMID: 33002950 Review.
-
Association between interleukin-12 p40 subunit and risk of primary Sjögren's disease: a Mendelian randomization study.Rheumatology (Oxford). 2025 Apr 1;64(4):2295-2299. doi: 10.1093/rheumatology/keae475. Rheumatology (Oxford). 2025. PMID: 39222420
-
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30. Lancet. 2022. PMID: 34861168 Clinical Trial.
-
Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now?BioDrugs. 2021 Nov;35(6):593-610. doi: 10.1007/s40259-021-00505-7. Epub 2021 Nov 3. BioDrugs. 2021. PMID: 34731460 Review.
References
Literatur
-
- Ritter J, Chen Y, Stefanski AL, Dorner T (2022) Current and future treatment in primary Sjogren’s syndrome—A still challenging development. Joint Bone Spine 89:105406. https://doi.org/10.1016/j.jbspin.2022.105406 - DOI - PubMed
-
- Fisher BA et al (2024) Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren’s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet 404:540–553. https://doi.org/10.1016/S0140-6736(24)01211-X - DOI - PubMed
-
- Seror R et al (2015) Validation of EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74:859–866. https://doi.org/10.1136/annrheumdis-2013-204615 - DOI - PubMed
-
- St Clair EW et al (2024) CD40 ligand antagonist dazodalibep in Sjogren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med 30:1583–1592. https://doi.org/10.1038/s41591-024-03009-3 - DOI